Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New chemotherapies in gastric adenocarcinoma

New chemotherapies in gastric adenocarcinoma Summary Chemotherapy is still the most important component of systemic therapy in gastric cancer. It is not replaced by targeted agents so far. Novel chemotherapies like 5‑fluorouracil (5FU) prodrugs are applied. Agents such as nanoliposomal irinotecan or nanoparticle albumin-bound paclitaxel are still under investigation. In patients overexpressing the epithelial growth factor receptor 2 (HER2), the addition of trastuzumab to classical chemotherapy improves overall survival (OS) substantially and in second line setting the monoclonal antibody ramucirumab shows single agent activity as well as activity in combination with paclitaxel. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

New chemotherapies in gastric adenocarcinoma

Wöll, Ewald
memo - Magazine of European Medical Oncology , Volume 10 (3): 4 – Sep 1, 2017
Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/new-chemotherapies-in-gastric-adenocarcinoma-M7stEb6kdT
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0354-0
Publisher site
See Article on Publisher Site

Abstract

Summary Chemotherapy is still the most important component of systemic therapy in gastric cancer. It is not replaced by targeted agents so far. Novel chemotherapies like 5‑fluorouracil (5FU) prodrugs are applied. Agents such as nanoliposomal irinotecan or nanoparticle albumin-bound paclitaxel are still under investigation. In patients overexpressing the epithelial growth factor receptor 2 (HER2), the addition of trastuzumab to classical chemotherapy improves overall survival (OS) substantially and in second line setting the monoclonal antibody ramucirumab shows single agent activity as well as activity in combination with paclitaxel.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Sep 1, 2017

References

  • Modified therapy with 5‑fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
    AM Murad, FF Santiago, A Petroianu
  • Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
    S Pyrhonen, T Kuitunen, P Nyandoto, M Kouri
  • Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
    B Glimelius, K Ekstrom, K Hoffman
  • Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data
    AD Wagner, W Grothe, J Haerting
  • Capecitabine and oxaliplatin for advanced esophagogastric cancer
    D Cunningham, N Starling, S Rao
  • Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
    E Cutsem, VM Moiseyenko, S Tjulandin
  • Capecitabine/cisplatin versus 5‑fluorouracil/cisplatin as firstline therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    YK Kang, WK Kang, DB Shin
  • Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT)
    E Woll, T Kuhr, W Eisterer
  • Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
    J Souglakos, K Syrigos, A Potamianou
  • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    F Lordick, YK Kang, HC Chung
  • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
    E Cutsem, S Haas, YK Kang
  • Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
    L Shen, J Li, J Xu
  • Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    T Waddell, I Chau, D Cunningham
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    YJ Bang, E Cutsem, A Feyereislova
  • Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
    MH Ryu, C Yoo, JG Kim
  • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    EC Smyth, M Verheij, W Allum
  • Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    PC Thuss-Patience, A Kretzschmar, D Bichev
  • Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
    HE Ford, A Marshall, JA Bridgewater
  • Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone
    JH Kang, SI Lee, DH Lim
  • Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
    S Hironaka, S Ueda, H Yasui
  • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    CS Fuchs, J Tomasek, CJ Yong
  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    H Wilke, K Muro, E Cutsem
  • Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
    J Li, S Qin, J Xu
  • Inzidenz und Mortalität bösartiger Neubildungen in Tirol Diagnosejahr 2013
    citation_title=Inzidenz und Mortalität bösartiger Neubildungen in Tirol Diagnosejahr
  • SEER cancer statistics review, 1975–2013
    citation_title=SEER cancer statistics review,
  • Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    D Cunningham, WH Allum, SP Stenning
  • Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial
    M Ychou, V Boige, JP Pignon
  • Neoadjuvant chemotherapy for resectable E/GEJ adenocarcinoma MRC OEO5 trial
    D Alderson
  • Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
    SE Al-Batran, RD Hofheinz, C Pauligk
  • Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine
    DD Hoff, T Ervin, FP Arena
  • Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
    K Shitara, A Takashima, K Fujitani
  • A phase I study of S‑1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer
    N Nakayama, K Ishido, K Chin
  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
    A Wang-Gillam, CP Li, G Bodoky
  • Randomized trial of TAS-102 for refractory metastatic colorectal cancer
    RJ Mayer, E Cutsem, A Falcone
  • A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)
    H Bando, T Doi, K Muro
  • Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts
    M Nukatsuka, F Nakagawa, H Saito
  • Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenografts
    M Nukatsuka, F Nakagawa, T Takechi
  • Nivolumab (ONO-4538/BMS-936558) as Salvage Treatment After Second- or Later-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer (AGC): A Double-Blinded, Randomized, Phase 3 Trial
    T Satoh